Skip to main content
Clinical Trials/NL-OMON41009
NL-OMON41009CompletedPhase 3

Intervention study to assess the effect of daily consumption of a lutein-enriched-egg beverage on maintenance of visual function in subjects with early signs of Age-related Macular Degeneration - I-TEAM (Intervention Trial in Early Age-related Macular degeneration)

ewtricious R&D0 sites20 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Enrollment
20

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • Early AMD (AREDS category 2)
  • o many small drusen, or
  • o a few intermediate-sized (63-124 micrometres in diameter) drusen, or
  • macular pigmentary changes
  • - Intermediate AMD (AREDS category 3)
  • o extensive intermediate sized (63-124 micrometres in diameter) drusen, or
  • o at least one large (>125 micrometres in diameter) drusen or
  • o geographic atrophy not involving the foveal centre
  • - men and women age >50 years
  • - BMI 18-35 kg/m2
  • - Vision > 20/40 for Snellen visual acuity

Exclusion Criteria

  • - ocular media opacity (severe cataract)
  • - history of active small bowel disease or resection
  • - atrophic gastritis
  • - history of hyperlipidemia or screening values as follows (LDL > 5.33mmol/L or 205mg/dL;
  • triglycerides > 4.52mmol/L or 400 mg/dL)
  • - hypertension (>150/90 mm Hg)
  • - diabetes mellitus (if also accompanied by signs of diabetic retinopathy)

Investigators

Sponsor
ewtricious R&D

Similar Trials